Introduction
============

Most silicosis patients are quarrying, coal mine, glass, ceramics factory workers because silicosis is an occupational disease caused by long-term exposure and inhalation of silica dust ([@b1-etm-0-0-8858],[@b2-etm-0-0-8858]). Silica dust enters the respiratory tract and alveoli by breathing, causing inflammation in the lungs, and then causing pulmonary fibrosis, which seriously affects the pulmonary function ([@b3-etm-0-0-8858]). According to statistics, the number of silicosis patients in developing countries has exceeded 600,000; the number of new cases has increased rapidly, and the rate of death from silicosis continues to increase ([@b4-etm-0-0-8858]). Silicosis is an irreversible chronic disease that continues to deteriorate. The treatment is based on the principle of avoiding complications as far as possible and needs long-term medication, and the quality of life of patients will be seriously affected with the development of the disease ([@b5-etm-0-0-8858]). The silicotic lung has the characteristics of high medical costs, high disability rate and high mortality rate, heavy financial burden and psychological pressure on the patient\'s family, and no special drugs have been developed for the treatment of silicosis so far, therefore, the treatment can only be the basis of controlling and delaying the development of the disease, and the main purpose is to improve the immune function and quality of life of patients at the same time ([@b6-etm-0-0-8858]). Dyspnea in silicosis patients is caused by obstruction of the airway, while the relevant Chinese literature shows that 6-min walk test (6MWT) is related to dyspnea, which can be used as an index to evaluate patient\'s exercise tolerance. 6MWT is currently an objective evaluation index for exercise tolerance in patients with chronic obstructive pulmonary disease, respiratory failure and other lung diseases ([@b7-etm-0-0-8858],[@b8-etm-0-0-8858]).

Acetylcysteine, the main active component of acetylcysteine effervescent tablets, is widely used in the treatment of many respiratory diseases, such as bronchial asthma, chronic obstructive pulmonary disease because it can dissolve concentrated phlegm ([@b9-etm-0-0-8858]). In addition, it has been reported that acetylcysteine has antioxidant and inhibitory effects on neutrophil chemotaxis in bronchial mucosa of silicosis patients ([@b10-etm-0-0-8858]). Tetrandrine, as an alkaloid, plays a major role in analgesia, anti-inflammation, and can effectively improve pulmonary vascular smooth muscle spasm, thereby improving pulmonary microcirculation, thus reducing clinical features such as cough and chest tightness in patients ([@b11-etm-0-0-8858],[@b12-etm-0-0-8858]).

Because most of the previous studies focused on lung ventilation and pulmonary function in silicosis patients, the clinical efficacy of acetylcysteine combined with tetrandrine tablets on the basis of conventional therapy in treatment of silicosis and the observation of exercise tolerance and pulmonary function in patients were conducted in this study to provide a certain theoretical basis and clues for the clinical application of drugs.

Patients and methods
====================

### Methods

In total, 248 cases of silicosis patients with an average age of 50.42±9.67 years and treated in Branch of Tai\'an City Central Hospital (Tai\'an, China) from October 2015 to 2017 were retrospectively analyzed in this study, including 226 males and 22 females. Further 116 cases with conventional therapy were the control group, and 132 cases treated with acetylcysteine and tetrandrine tablets on the basis of conventional therapy were the observation group. There was no significant difference in general information between the two groups (P\>0.05). All patients met the criteria for diagnosis and staging of silicosis ([@b13-etm-0-0-8858]). The cases were excluded due to pregnancy, lactation, other tumors, liver and kidney dysfunction, emphysema, pulmonary tuberculosis and other lung related diseases. Patients with incomplete clinical data or lost to follow-up were also excluded. This study was approved by the Ethics Committee of the hospital. All the subjects were informed and agreed to participate in the clinical study, and the patients and their families signed a fully informed consent form. General information is provided in [Table I](#tI-etm-0-0-8858){ref-type="table"}.

### Medicines and instruments

Ambroxol Hydrochloride oral liquid was from Hong Kong Bright Future Pharmaceutical Laboratories Limited (SFDA approval no. H20067008). Xiaokechuan tablet was from the sixth pharmaceutical factory of Harbin Pharmaceutical Group Co., Ltd. (SFDA approval no. Z23021362). Acetylcysteine effervescent tablets and tetrandrine were from Zhejiang Jinhua Conba Biopharma Co., Ltd. (SFDA approval no. H20057334, SFDA approval no. H33022075). British BTL08 lung function instrument was from Chengdu Buywells Science and Technology Co., Ltd.

### Treatment methods

All patients stayed at home and stopped working during treatment, avoiding contact with silica dust and severely damaging working environment. All patients took the medicine on time, did not take other health care products or medicines privately, and did not use other means of recovery. The daily intake of the diet was light and varied. The control group was treated with conventional therapy: Dosage of ambroxol hydrochloride oral liquid 10 ml/time, 2 times daily. At the same time, Xiaokechuan tablet were taken orally 4 tablets/time, 3 times daily. The observation group was treated with acetylcysteine and tetrandrine tablets on the basis of routine treatment: Dosage of acetylcysteine effervescent tablets 0.6 g/time, 2 times daily; dosage of tetrandrine tablets 100 mg/time, 2 times daily. After 6 days, the drug was stopped for 1 day. The two groups were treated with 4 courses for 8 months. The treatment course of the patient was decided by the attending doctor according to the condition of the patient, and the treatment time was adequate ([@b14-etm-0-0-8858]).

### Evaluation of clinical efficacy, adverse reactions and side effects

The respiratory symptoms 1 week before and after treatment of the two groups were evaluated according to the internationally accepted St. George\'s Respiratory questionnaire (SGRQ) ([@b15-etm-0-0-8858]), including chest tightness, chest pain, cough and sputum production.

Improvement rate = (number of patients with the above symptoms before treatment, number patients with the above symptoms after treatment)/number of patients with the above symptoms before treatment x100%.

Side effects of the drug include mild lethargy, fatigue, epigastric discomfort, nausea and vomiting.

### Evaluation of pulmonary function

Pulmonary function before and after treatment was measured by pulmonary function instrument, including the following indicators: Forced vital capacity (FVC) and forced expiratory volume in 1 sec (FEV1).

### Evaluation of exercise tolerance

Exercise tolerance before and after treatment was measured by 6MWT ([@b16-etm-0-0-8858]). A straight line of 30 m long was drawn on the indoor floor with a marker at each end, and the patient controlled the speed and walked along the line to and fro. The walking distance within 6 min was calculated.

### Statistical analysis

Statistical analysis was carried out using SPSS 19.0 (IBM, Corp.) software. The count data were expressed as \[n(%)\], and analyzed with the χ^2^ test. The measurement data were expressed as (mean ± SD). The data of the two groups were compared by t-test, and the data of multiple groups were compared by Oneway ANOVA. P\<0.05, indicates a statistically significant difference.

Results
=======

### Clinical symptoms and adverse reactions of the two groups before and after treatment

The symptoms of chest tightness, chest pain, cough and sputum production in the observation group and the control group after treatment were significantly lower than those before treatment, the difference was statistically significant (P\<0.05). There was no significant difference in chest tightness, chest pain, cough and sputum production between the two groups before treatment (P\>0.05). The improvement rate of chest tightness, chest pain, cough and sputum production in the observation group after treatment was significantly higher than that in the control group, and the difference was statistically significant (P\<0.05).

According to the follow-up results, the control group did not have adverse reactions during the treatment period; in the observation group, there were 4 patients with adverse reactions such as nausea, abdominal pain and abdominal distension during treatment. One of them had an increase in transaminase activity, the adverse reaction disappeared 1 month after the drug was stopped according to the doctor\'s advice. According to the results of reexamination, there was no significant changes in ECG, renal function, and blood routine indicators between the observation group and the control group ([Table II](#tII-etm-0-0-8858){ref-type="table"}).

### Exercise tolerance and pulmonary function before and after treatment in the groups

The 6MWT, FVC and FEV1 in the observation group and the control group after treatment was significantly higher than that before treatment, and the difference was statistically significant (P\<0.001). There was no significant difference in 6MWT, FVC, FEV1 between the two groups before treatment (P\>0.05). The 6MWT, FVC and FEV1 in the observation group after treatment was significantly higher than that in the control group, and the difference was statistically significant (P\<0.001) ([Table III](#tIII-etm-0-0-8858){ref-type="table"} and [Figs. 1](#f1-etm-0-0-8858){ref-type="fig"} and [2](#f2-etm-0-0-8858){ref-type="fig"}).

### Side effects after treatment in the groups

The comparison of the two groups showed that the incidence of drug side effects in the observation group was significantly lower than that in the control group (P\<0.05) ([Table IV](#tIV-etm-0-0-8858){ref-type="table"}).

Discussion
==========

Pulmonary fibrosis is the main clinical manifestation of silicosis which will exacerbate with the prolongation of the course of disease. First of all, the pulmonary blood circulation is blocked, which damages the defense system of the respiratory tract, and results in the decrease of the patient\'s immune function, the formation of repeated infection, and even irreversible pulmonary failure in severe patients ([@b17-etm-0-0-8858],[@b18-etm-0-0-8858]). Because silicosis has no typical clinical symptoms in the early stage and no special drug treatment, it is already serious when the symptoms of chest tightness, chest pain, cough, sputum production, etc. emerge ([@b19-etm-0-0-8858]). Airway obstruction of respiratory system in silicosis patients also affects motor function. Therefore, inhibition of pulmonary fibrosis is the main criterion for treatment of silicosis. The efficacy of acetylcysteine combined with tetrandrine tablets on the basis of conventional therapy in the treatment of silicosis was evaluated for clinical efficacy, exercise tolerance and pulmonary function in patients.

No other studies have been found to verify the effect of acetylcysteine combined with tetrandrine tablets on 6MWT in patients with silicosis. However, this study showed that the 6MWT in the observation group and the control group after treatment was significantly higher than that before treatment, and the difference was statistically significant (P\<0.001). There was no significant difference in 6MWT between the two groups before treatment (P\>0.05). The 6MWT in the observation group after treatment was significantly higher than that in the control group, and the difference was statistically significant (P\<0.001). The results showed that the improvement of motor function by the combined treatment of these two drugs was better than that by conventional therapy. In addition, the symptoms of chest tightness, chest pain, cough and sputum production in the observation group and the control group after treatment were significantly lower than those before treatment, and the difference was statistically significant (P\<0.05). There was no significant difference in chest tightness, chest pain, cough and sputum production between the two groups before treatment (P\>0.05). The improvement rate of chest tightness, chest pain, cough and sputum production in the observation group after treatment was significantly higher than that in the control group, and the difference was statistically significant (P\<0.05). The FVC and FEV1 in the observation group and the control group after treatment were significantly higher than those before treatment, and the difference was statistically significant (P\<0.001). There was no significant difference in FVC and FEV1 between the two groups before treatment (P\>0.05). FVC and FEV1 in the observation group after treatment were significantly higher than those in the control group, and the difference was statistically significant (P\<0.001). The findings of Weiss *et al* ([@b20-etm-0-0-8858]) and Luckhardt *et al* ([@b21-etm-0-0-8858]) are consistent with ours. In their studies, the improvement rate of cough, sputum, chest tightness, chest pain and dyspnea after treatment with acetylcysteine combined with tetrandrine was significantly higher than that in the control group; the FVC, FEV1 and FEV1/FVC in the treatment of silicosis with acetylcysteine combined with tetrandrine tablets after treatment were significantly improved compared with those before treatment in the observation group, and the degree of improvement in the observation group was higher than that in the control group, and the difference was statistically significant. These results suggested that acetylcysteine combined with tetrandrine tablets was effective in the treatment of silicosis and could improve the clinical symptoms and pulmonary function. According to literature, the destruction of the structure and function of the tracheal mucosa in silicosis patients is caused by the release of toxic substances by neutrophils in the bronchial mucosa, while acetylcysteine can control the inflammatory factors in patients\' serum, and exert antioxidant and antiinflammatory effects to slow down the development of the disease ([@b22-etm-0-0-8858]). Zhang *et al* ([@b23-etm-0-0-8858]) showed that acetylcysteine reduced the reactive oxygen species in rats exposed to silica, and also inhibited the mitochondrial apoptotic pathway, thereby reducing the severity of pulmonary fibrosis. Tetrandrine is a calcium antagonist that blocks the calcium channel of fiber cells and inhibits their proliferation ([@b24-etm-0-0-8858]). Moreover, it can inhibit collagen synthesis in silicosis tissue and act on cell microtubules to make collagen form fibrous structure only outside the cells, and reduce collagen protein in silicosis tissue and loosen or even degrade the tubercle of patients with silicotic nodules. Tetrandrine can inhibit various diseases such as hypertension, silicosis and arthritis, and has a good prospect of protecting liver cells, resisting liver fibrosis, reducing portal hypertension, inducing tumor cell apoptosis and reversing multidrug resistance ([@b25-etm-0-0-8858]). The role of tetrandrine in various signal transduction pathways such as reactive oxygen species, enhanced autophagy flux, multidrug resistance reversal, caspase pathway, cell cycle arrest, and calcium channel modification has been demonstrated ([@b26-etm-0-0-8858]). As a result, the patients with silicotic nodules who received tetrandrine were effectively improved, shadow decreased and faded, and symptoms such as chest tightness and cough were alleviated ([@b27-etm-0-0-8858]).

In conclusion, acetylcysteine combined with tetrandrine tablets on the basis of conventional therapy in treatment of silicosis is more effective than conventional therapy alone, which can also improve exercise tolerance, pulmonary function and clinical symptoms such as chest tightness, chest pain, cough, sputum production of silicosis patients, and is helpful for clinical application.
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![Comparison of exercise tolerance between the two groups before and after treatment. The results showed that the 6MWT in the observation group and the control group after treatment was significantly higher than that before treatment, and the difference was statistically significant (P\<0.001). There was no significant difference in 6MWT between the two groups before treatment (P\>0.05). The 6MWT in the observation group after treatment was significantly higher than that in the control group, and the difference was statistically significant (P\<0.001). ^\*^P\<0.001 compared with 6MWT after treatment in the control group. 6MWT, 6-min walk test.](etm-20-02-1285-g00){#f1-etm-0-0-8858}

![Comparison of pulmonary function between the two groups before and after treatment. The results showed that (A) the FVC in the observation group and the control group after treatment were significantly higher than that before treatment, and the difference was statistically significant (P\<0.001). There was no significant difference in FVC between the two groups before treatment (P\>0.05). FVC in the observation group after treatment was significantly higher than that in the control group, and the difference was statistically significant (P\<0.001). (B) The FEV1 in the observation group and the control group after treatment were significantly higher than those before treatment, and the difference was statistically significant (P\<0.001). There was no significant difference in FVC between the two groups before treatment (P\>0.05). The FEV1 in the observation group after treatment was significantly higher than that in the control group, and the difference was statistically significant (P\<0.001). ^\*^P\<0.001 with the FVC and FEV1 in the control group after treatment. 6MWT, 6-min walk test; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec.](etm-20-02-1285-g01){#f2-etm-0-0-8858}

###### 

General information (n).

  Factors                     Observation group (n=132)   Control group (n=116)   χ^2^ value   P-value
  --------------------------- --------------------------- ----------------------- ------------ ---------
  Age (years)                                                                     0.183        0.703
       \<50                   59                          55                                    
       ≥50                    73                          61                                    
  Sex                                                                             1.051        0.374
       Male                   118                         108                                   
       Female                 14                          8                                     
  Stage                                                                           0.267        0.878
       Ⅰ                      84                          76                                    
       Ⅱ                      32                          25                                    
       Ⅲ                      16                          15                                    
  Dust exposure time (year)                                                       0.283        0.678
       \<10                   94                          79                                    
       ≥10                    38                          37                                    
  Complication                                                                    1.051        0.374
       Yes                    14                          8                                     
       No                     118                         108                                   
  Smoking                                                                         0.762        0.683
       Past smoker            79                          65                                    
       Current smoker         24                          20                                    
       Never smoked           29                          31                                    

###### 

Clinical symptoms of the both groups before and after treatment (n).

  Indicator                   Observation group   Control group   χ^2^ value   P-value
  --------------------------- ------------------- --------------- ------------ ---------
  Chest tightness             132                 116             4.616        0.035
       Before treatment       124                 109                           
       After treatment        77                  82                            
       Improvement rate (%)   37.90               24.77                         
  Chest pain                                                      6.853        0.013
       Before treatment       117                 104                           
       After treatment        62                  73                            
       Improvement rate (%)   47.01               29.81                         
  Cough                                                           17.768       \<0.001
       Before treatment       121                 102                           
       After treatment        35                  58                            
       Improvement rate (%)   71.07               43.14                         
  Sputum production                                               13.873       \<0.001
       Before treatment       128                 105                           
       After treatment        42                  60                            
       Improvement rate (%)   67.19               42.86                         

###### 

Exercise tolerance and pulmonary function in both groups before and after treatment.

  Groups              Cases   Treatment duration   6MWT (m)                                                     FVC (L)                                                   FEV1 (L)
  ------------------- ------- -------------------- ------------------------------------------------------------ --------------------------------------------------------- ---------------------------------------------------------
  Observation group   132     Before treatment     323.24±25.83                                                 2.45±0.46                                                 1.62±0.45
                              After treatment      400.67±31.27^[a](#tfn1-etm-0-0-8858){ref-type="table-fn"}^   3.84±0.57^[a](#tfn1-etm-0-0-8858){ref-type="table-fn"}^   2.14±0.52^[a](#tfn1-etm-0-0-8858){ref-type="table-fn"}^
                              t value              21.93                                                        21.80                                                     8.688
                              P-value              \<0.001                                                      \<0.001                                                   \<0.001
  Control group       116     Before treatment     320.13±28.46                                                 2.44±0.39                                                 1.59±0.41
                              After treatment      355.71±30.28                                                 2.69±0.48                                                 1.83±0.51
                              t value              9.222                                                        4.354                                                     3.950
                              P-value              \<0.001                                                      \<0.001                                                   \<0.001

^a^P\<0.001 compared with the control group after treatment. 6MWT, 6-min walk test; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec.

###### 

Pulmonary function in both groups before and after treatment.

  Groups              Cases   Treatment duration   FVC (L)                                                   FEV1 (L)
  ------------------- ------- -------------------- --------------------------------------------------------- ---------------------------------------------------------
  Observation group   132     Before treatment     2.45±0.46                                                 1.62±0.45
                              After treatment      3.84±0.57^[a](#tfn2-etm-0-0-8858){ref-type="table-fn"}^   2.14±0.52^[a](#tfn2-etm-0-0-8858){ref-type="table-fn"}^
                              t value              21.80                                                     8.688
                              P-value              \<0.001                                                   \<0.001
  Control group       116     Before treatment     2.44±0.39                                                 1.59±0.41
                              After treatment      2.69±0.48                                                 1.83±0.51
                              t value              4.354                                                     3.950
                              P-value              \<0.001                                                   \<0.001

^a^P\<0.001 compared with the FVC and FEV1 in the control group after treatment. FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec.
